XML 184 R120.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Segment Information (Details 1) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015
Geographic information |  |  |  |  |  |  |  |  |  |  |
Product, net | $ 2,712.4 | $ 2,622.5 | $ 2,639.7 | $ 2,380.1 | $ 2,502.9 | $ 2,539.6 | $ 2,466.0 | $ 2,309.4 | $ 10,354.7 | $ 9,817.9 | $ 9,188.5
Revenues from anti-CD20 therapeutic programs | 415.0 | 406.5 | 397.1 | 340.6 | 318.2 | 317.6 | 349.2 | 329.5 | 1,559.2 | 1,314.5 | 1,339.2
Other revenues | 179.6 | $ 48.8 | $ 41.6 | $ 90.0 | 50.9 | $ 98.6 | $ 79.0 | $ 87.9 | 360.0 | 316.4 | 236.1
Long-lived assets | 3,182.4 |  |  |  | 2,501.8 |  |  |  | 3,182.4 | 2,501.8 | 2,187.6
U.S |  |  |  |  |  |  |  |  |  |  |
Geographic information |  |  |  |  |  |  |  |  |  |  |
Product, net |  |  |  |  |  |  |  |  | 7,017.1 | 7,050.4 | 6,545.8
Revenues from anti-CD20 therapeutic programs |  |  |  |  |  |  |  |  | 1,475.6 | 1,249.5 | 1,269.8
Other revenues |  |  |  |  |  |  |  |  | 249.5 | 224.7 | 142.0
Long-lived assets | 1,226.9 |  |  |  | 1,272.3 |  |  |  | 1,226.9 | 1,272.3 | 1,296.5
Europe |  |  |  |  |  |  |  |  |  |  |
Geographic information |  |  |  |  |  |  |  |  |  |  |
Product, net |  |  |  |  |  |  |  |  | 2,844.8 | 2,237.2 | 2,165.7
Revenues from anti-CD20 therapeutic programs |  |  |  |  |  |  |  |  | 0.6 | 1.9 | 3.5
Other revenues |  |  |  |  |  |  |  |  | 67.8 | 71.5 | 31.2
Long-lived assets | 1,948.2 |  |  |  | 1,221.1 |  |  |  | 1,948.2 | 1,221.1 | 881.7
Asia |  |  |  |  |  |  |  |  |  |  |
Geographic information |  |  |  |  |  |  |  |  |  |  |
Product, net |  |  |  |  |  |  |  |  | 160.1 | 217.3 | 143.7
Revenues from anti-CD20 therapeutic programs |  |  |  |  |  |  |  |  | 0.0 | 0.0 | 0.0
Other revenues |  |  |  |  |  |  |  |  | 42.7 | 20.2 | 62.9
Long-lived assets | 5.2 |  |  |  | 7.0 |  |  |  | 5.2 | 7.0 | 7.7
Other |  |  |  |  |  |  |  |  |  |  |
Geographic information |  |  |  |  |  |  |  |  |  |  |
Product, net |  |  |  |  |  |  |  |  | 332.7 | 313.0 | 333.3
Revenues from anti-CD20 therapeutic programs |  |  |  |  |  |  |  |  | 83.0 | 63.1 | 65.9
Other revenues |  |  |  |  |  |  |  |  | 0.0 | 0.0 | 0.0
Long-lived assets | $ 2.1 |  |  |  | $ 1.4 |  |  |  | $ 2.1 | $ 1.4 | $ 1.7

X
- Definition Revenues from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada. + References No definition available. + Details
Name: | biib_RevenuesfromantiCD20therapeuticprograms
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599 + Details
Name: | us-gaap_NoncurrentAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a),(d)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_OtherSalesRevenueNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_SalesRevenueGoodsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentsGeographicalAreasAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_AsiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |